

J Neural Transm (2012) 119:507–515
DOI 10.1007/s00702-011-0699-1

BIOLOGICAL CHILD AND ADOLESCENT PSYCHIATRY - ORIGINAL ARTICLE

Pilot study on HTR2A promoter polymorphism, –1438G/A (rs6311) and a nearby copy number variation showed association with onset and severity in early onset obsessive–compulsive disorder

Susanne Walitza · Daniel Sabanés Bové · Marcel Romanos · Tobias Renner · Leonhard Held · Michael Simons · Christoph Wewetzer · Christian Fleischhaker · Helmut Remschmidt · Andreas Warnke · Edna Grünblatt

Received: 25 March 2011 / Accepted: 8 August 2011 / Published online: 28 August 2011
© Springer-Verlag 2011

Abstract A previous study showed that a single nucleotide polymorphism (SNP), –1438G/A (rs6311), found in the transcriptional control region of the gene that encodes the serotonin-receptor 2A (HTR2A) was associated with obsessive–compulsive disorder (OCD) in a sample of children and adolescents. In this study, we reanalyzed the association of this SNP with OCD in an enlarged population of 136 cases (55 previous + 81 new cases) and compared them to 106 newly recruited, healthy, age-matched controls. We also investigated whether this SNP or its copy number variations (CNV) was associated with OCD severity and age of onset. The CNV was analyzed in a DNA region located near rs6311. The results confirmed the association between the A-allele and early onset OCD in

children and adolescents, with an odds ratio (OR) of 1.69 [95% CI (1.17, 2.46); $p = 0.005$]. Strikingly, we found that carriers of one copy (deletion) of the CNV were associated with a very early onset OCD (2.5 years earlier than the typical onset), and they had increased CY-BOCS scores (8.7 points higher compared to “normal” CNV and duplications); which is related to increased severity of OCD symptoms ($p = 0.031$; $p = 0.004$, respectively). Compared to the normal CNV and duplications, the association between the deletion and OCD showed an OR of 7.56 [95% CI (1.32, 142.84); $p = 0.020$]. These results pointed to the functional importance of this promoter region of HTR2A; it influenced the occurrence, the onset, and the severity of OCD.

S. Walitza (✉) · E. Grünblatt
Hospital of Child and Adolescent Psychiatry,
University of Zurich, Neumuensterallee 9,
8032 Zurich, Switzerland
e-mail: Susanne.walitza@kjpdzh.ch

D. S. Bové · L. Held
Division of Biostatistics, Institute for Social
and Preventive Medicine, University of Zurich,
Hirschengraben 84, 8001 Zurich, Switzerland

M. Romanos · T. Renner · A. Warnke
Department of Child and Adolescent Psychiatry,
University of Wuerzburg, 97080 Wuerzburg, Germany

M. Romanos
Department of Child and Adolescent Psychiatry,
University of Munich, 80336 Munich, Germany

M. Simons
Department of Child and Adolescent Psychiatry,
Psychosomatics and Psychotherapy, RWTH Aachen,
Neuenhofer Weg 21, 52074 Aachen, Germany

C. Wewetzer
Municipal Hospitals of Cologne,
Clinic for Child and Adolescent Psychiatry
and Psychotherapy, Florentine-Eichler-Str. 1,
51067 Köln, Germany

C. Fleischhaker
Department of Child and Adolescent Psychiatry,
University Freiburg, 79104 Freiburg, Germany

H. Remschmidt
Department of Child and Adolescent Psychiatry,
Philipps-University Marburg, 35039 Marburg, Germany

E. Grünblatt
Clinical Neurochemistry Laboratory,
Clinic and Policlinic for Psychiatry,
Psychosomatic and Psychotherapy,
University of Wuerzburg,
97080 Wuerzburg, Germany

Keywords Obsessive–compulsive disorder · HTR2A polymorphism · Child and adolescent psychiatry · Copy number variation

Introduction

Obsessive–compulsive disorder (OCD) is a heterogeneous psychiatric disorder characterized by clinically significant, recurrent, intrusive, and disturbing thoughts (obsessions), accompanied by repetitive, stereotypic behaviors, usually associated with anxiety or dread (compulsions) (American Psychiatric Association 1996). According to the National Comorbidity Survey Replication, the median age of OCD onset is 19 years. However, symptoms of OCD often begin during childhood or adolescence; 21% of all cases start experiencing symptoms by age 10 years old (Kessler et al. 2005). The early onset OCD often develops a chronic course and has a poor long-term outcome. According to a review of twin studies (van Grootheest et al. 2005), the authors concluded that the heritability for obsessive compulsive symptoms ranges from 0.45 to 0.65 in children and from 0.27 to 0.47 in adults. Grados and colleagues (2007) summarized that family studies showed OCD five- to sevenfold more frequent in relatives of patients than in relatives of controls. In accord to the results of twin studies, in family studies, the earlier age of onset of OCD in the index patients was correlated with a higher prevalence of OCD in first-degree relatives (Walitza et al. 2010). However, there is a wide range of prevalence rates of OCD in first-degree relatives across different studies, which merits discussion. The definition of early onset OCD differs among studies at the cut-off for age of onset; under 7 years of age was the lowest and under 18 years of age was the highest age as definition criteria. Furthermore, e.g. including different comorbidities as tic-disorders could have some effects on formal and molecular genetic results. Heterogeneity of the phenotype, the young age of siblings in studies of childhood OCD patients may result in an over/underestimation of the prevalence of OCD in relatives.

Dysfunction of the serotonin (5-HT) system has been implicated in OCD and is thought to contribute to behavioral traits, like perfectionism, obsessiveness, anxiety, and depression (Serretti et al. 2007; Zohar et al. 2000). Selective serotonin re-uptake inhibitors (SSRI; e.g. fluoxetine) that block the serotonin transporter represent the most effective pharmacological treatment of OCD, early onset OCD, and anxiety disorders (Geller et al. 2003; Pediatric OCD Treatment Study (POTS) Team 2004). Therefore, most genetic association studies in OCD have investigated genes related to serotonergic signaling. Although there is extensive evidence that the heritability of early onset OCD

is higher than the heritability of adult onset OCD association studies in early onset OCD are comparably rare.

Our group previously conducted an association study within a case–control design to determine whether early onset OCD was associated with the single nucleotide polymorphism (SNP), –1438A/G (rs6311), in the serotonin receptor 2A (HTR2A) promoter (Walitza et al. 2002). We detected a significant association between OCD and the A-allele of 1438A/G (Walitza et al. 2002). Our results were in accordance with the results from a study conducted by Enoch and colleagues in adult patients with OCD as well as in early onset OCD determined retrospectively (Enoch et al. 1998, 2001). However, several other case–control association studies on adult OCD patients (Denys et al. 2006; Saiz et al. 2008a; Tot et al. 2003) reported no association with SNP rs6311 as well as negative transmission-disequilibrium tests (Dickel et al. 2007). Similarly, several association studies for the synonymous T102C (rs6313) variant, which was reported to be in complete linkage disequilibrium with rs6311 in different populations (Spurlock et al. 1998; Meira-Lima et al. 2004; Martinez-Barrondo et al. 2005; Saiz et al. 2008b), reported conflicting results in adult OCD patients (Tot et al. 2003; Meira-Lima et al. 2004; Hemmings et al. 2003; Frisch et al. 2000; Saiz et al. 2008a; Hemmings et al. 2006). Since Kato and colleagues (1996) presented evidence for genomic imprinting (complete inactivation of one allele) of the HTR2A, several studies investigate the effects of the 5HTR2A imprinting on expression, but up to now conflicting results have been reported. Bunzel and colleagues (1998) showed in 4 out of 18 post-mortem brain tissues monoallelic expression of the HTR2A due to polymorphic imprinting in the brain. Other authors suggested that HTR2A is unlikely to have any polymorphisms that alter gene expression in the brain in an allele-dependent pattern (Bray et al. 2004). But CpG sites, which are apparently potential target regions for methylation have been detected within the rs6311 polymorphism are relevant for expression pattern (Bray et al. 2004; Polesskaya et al. 2006). In contrast to the findings of Bunzel et al. (1998), de Luca et al. (2007) found no evidence of genomic imprinting in a sample of 29 heterozygous psychotic patients and 16 heterozygous controls. The authors concluded that complete polymorphic imprinting of the HTR2A gene may be a rare event. Although there are conflicting perspectives regarding imprinting of the HTR2A we decided to enlarge our previous sample with early onset OCD to reinvestigate the association with the 5HT2A promoter polymorphism. In parallel, we focused on a copy number variation (CNV) near the rs6311 promoter region. Recent investigations have implicated de novo and/or rare CNVs as potentially pathogenic factors in attention-deficit/hyperactivity disorder (ADHD) (Williams et al. 2010; Lesch et al. 2011), autism

(Stankiewicz and Lupski 2010; Pinto et al. 2010), and schizophrenia (Lee et al. 2010). Rare CNV is defined having lower frequency than 1% in the population, while common CNV also referred as polymorphism has higher frequency (Beckmann et al. 2007). The duplication or deletion process of CNVs can disrupt a variable number of genes, which can result in alternate gene products or changes in gene dosage. Moreover, the disruption of regulatory regions in the genome can lead to altered gene expression, and this may contribute to disease predisposition. Given the highly heritable and variable nature of OCD, we hypothesized that individual, CNVs near the SNP rs6311 might contribute to OCD risk and severity. Therefore, after searching for CNVs reported in the Database of Genomic Variants (DGV; <http://projects.tcag.ca/variation/>) site as well as other CNVs in the HTR2A gene or in its vicinity, that resulted in no known CNV, we aimed to detect new putative CNV using the pre-designed TaqMan CNV-assay (Applied Biosystems Co., Germany) that correspond to the nearest CNV to the SNP (68-bp upstream of SNP rs6311, while amplicon size was 100 bp) and still on the promoter region (Fig. 1), assuming that this region is of functional relevance.

In the present study, we extended the number of patients included in our previous study (Walitza et al. 2002) and also included new independent controls. We aimed to confirm our previous results of the association between the

rs6311 polymorphism and early onset OCD. In addition, we aimed to investigate the association between early onset OCD and the not yet described CNV located near SNP rs6311 on the HTR2A promoter.

Materials and methods

Subjects

The study sample comprised patients that had received inpatient treatment at the Department of Child and Adolescent Psychiatry of the Universities of Würzburg, Marburg, Aachen, and Freiburg. All patients and healthy controls were of German ethnicity. All participants and the parents of minors gave written informed consent. The ethics committees of all participating universities approved the study.

Patients fulfilled the diagnostic criteria for current OCD according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) (1996) and the International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10) (Dilling et al. 1996). To describe the broad range of clinical features, we ascertained systematically initial symptoms from baseline with psychopathology schemes as CASCAP-D (Döpfner et al. 1999). To assess the criteria for OCD and




Fig. 1 Alignment of CNV and SNP rs6311 on the HTR2A promoter sequence and their effects on transcription factors. **a** The alignment of HTR2A on chromosome 13. **b** The HTR2A gene alignment with its promoter region (not to scale). **c** The promoter region with the CNV

and rs6311 alignment (not to scale); the indicated transcription factors may be affected according to PROMO version3 (<http://algenn-lsi.ups.es>). Red G-allele, green A-allele, + gain, – loss, of transcription factors (according to Piva et al. 2010)

comorbid psychiatric disorders, both patients and parents were interviewed separately with the semi-structured diagnostic interview of psychiatric disorders in children and adolescent (Kinder-DIPS; children and parents version) (Unnewehr et al. 1995). The Kinder-DIPS is used to assess a wide range of psychiatric disorders in childhood and adolescence, including ADHD, and conduct and oppositional-, anxiety-, affective-, eating- and tic-disorders, diagnosed according to the criteria of the ICD-10 (Dilling et al. 1996). The Kinder-DIPS further includes a general clinical screening component to assess substance use, abuse, psychosis and somatic diseases. Autistic spectrum disorders were screened within the ascertainment of psychopathology (CASCAP-D) (Döpfner et al. 1999).

The Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) (Scahill et al. 1997) was used to assess further characteristics and severity of OCD. A summary score above 16 points was determined to be the cut-off for clinical impairment caused by OCD symptomatology; a score of 38 points was the maximum for describing severity according to the CY-BOCS. Of note, the DSM-IV does not require children to fulfill the criterion of insight regarding the irrationality of the symptoms. This may result in low summary scores; therefore, it is possible that the CY-BOCS evaluations underestimated the true severity of symptomatology. For diagnostic assessments of present and lifetime Tourette's Syndrome and tic-disorders, we used the adapted German version (Hebebrand et al. 1997) of the Child and Adult Schedule for Tourette and Other Behavioral Syndromes (STOBS), according to Pauls et al. (1991).

All interviews were performed by senior clinicians of the university clinics for child and adolescent psychiatry. Subjects with comorbid disorders were only included in the study when the OCD symptoms were most prominent, based on two criteria: (1) OCD had to predate the onset of the comorbid disorders (except ADHD), and (2) two senior clinicians independently diagnosed the predominance of the OCD symptoms.

Exclusion criteria for patients were: lifetime history of psychotic disorders, Gilles-de-la-Tourette's syndrome and chronic tic-disorder, autistic spectrum disorder (e.g. infantile autism, atypical autism, Asperger's syndrome), alcohol dependence, or mental retardation ($IQ < 70$).

The patient sample consisted of 136 patients (children and adolescents). The patient sample was a superset that comprised 55 children with OCD from a previous study (Walitza et al. 2002), plus 81 newly recruited children with OCD.

In a previous case-control study regarding the $-1438G/A$ polymorphism in early onset OCD (Walitza et al. 2002), the control group consisted of students that were older than the patients. For this study, we recruited

106 healthy German children from the Department of Child and Adolescent Psychiatry of the University of Würzburg to use as new independent controls. They were screened with the Child Behavior Checklist (CBCL) (Döpfner et al. 1991) and a validated German depression self-rating inventory (DIKJ) (Stiensmeier-Pelster et al. 2000). All controls and their mothers were interviewed with the Schedule for Affective Disorders and Schizophrenia for school-aged children (Kiddie-Sads) (Kaufman et al. 1997). The intelligence level was assessed with the Culture Fair Test (CFT 1/20) (Cattell et al. 1997). Exclusion criteria for participation of controls were: any severe somatic or neurological disease; any psychiatric diagnosis according to the Kiddie-Sads; a DIKJ score that exceeded the threshold of 18 for clinically relevant depressive symptoms; any T-score above 63 on the internalizing, externalizing, or total score of the CBCL; or an IQ below 80.

Genotyping for the HTR2A $-1438 A/G$ polymorphism

Genomic DNA was extracted from whole blood with the desalting Proteinase K methodology (Miller et al. 1988). Genotyping for the $-1438 A/G$ polymorphism (rs6311) (location 47,471,478 on the GRCh37; 13q14 q21) was conducted with the TaqMan[®] SNP genotyping assay (Assay no. C-8695278-10; Applied Biosystems Co.) on the iCycler iQ Real-Time thermocycler (BioRad Laboratories Inc., Germany), according to manufacturer instructions. Genotypes were assessed according to the Allelic discrimination method with the iCycler IQ software (version 3.1.7050; BioRad Laboratories).

CNV analysis

The CNV located 68 bp upstream of SNP rs6311 (location 47,471,310-47,471,410 on GRCh37; 13q14.2a; amplicon size 100 bp; Fig. 1) was analyzed with the TaqMan[®] Copy Number Assay (Assay no. Hs06366812_cn; Applied Biosystems Co.) on the iCycler iQ Real-Time thermocycler (BioRad Laboratories Inc.), according to manufacturer instructions. Each sample was adjusted to 20 ng genomic DNA per well. The TaqMan[®] Copy Number Reference assay for RNase P was used for normalization. Four replicates were run per sample. The CNV per sample were evaluated by the Cycles threshold (C_T) values assigned with the CopyCaller[®] software (version 1.0; Applied Biosystems Co.). A "normal" CNV was defined as two copies; a "low" CNV was defined as ≤ 1 copy (deletion); and a "high" CNV was defined as ≥ 3 copies (duplication). For each sample, an independent replication of the assay was conducted in order to eliminate false determinations of CNV.

Statistical analysis

All statistical tests were two-sided with an alpha-level of 0.05. The results were unadjusted for multiple testing, because the analysis was exploratory and the number of tests was comparably small. The association study of the SNP was a replication study. Assuming an OCD prevalence of 2% and a disease allele frequency of 50%, we have a power of 91.1% for detecting an odds ratio (OR) of at least 2 using Armitage's trend test and only the 81 new patients (Slager and Schaid 2001). This was analyzed primarily by omitting the cases analyzed in the previous study that gave similar significant results (data not shown). Secondly, we analyzed the complete sample. All confidence intervals were 95% profile likelihood intervals (Pawitan 2001).

Gender and age distributions were compared with Fisher's exact test and the Student's *t* test, respectively. Differences in average OCD onset and severity (measured by the CY-BOCS score) were assessed with one- and two-way ANOVAs for separate and simultaneous comparisons, respectively. In the case-control analysis, discrepancies in SNP and CNV distributions were separately tested with Armitage's trend test and Fisher's exact test, respectively (Sasieni 1997). Logistic regression for a simultaneous association analysis of SNP and CNV with OCD assumed an additive model for SNP and an unrestricted model for CNV. An additional interaction of SNP with gender was tested with the Student's *t* test.

The computations were performed with the statistical computing software R (R Development Core Team 2010), version 2.11.0.

Results

Demographic data

The study population included slightly more males than females in both the OCD and the healthy control groups ($p = 0.51$; Table 1). The healthy controls were significantly younger than the patients with OCD ($p < 0.0001$; Table 1); however, the average age of the controls was not significantly different from the average age of the patients at OCD onset ($p = 0.21$; Table 1). For the comorbidities and gender data, see Table 1.

Case-control analysis of the HTR2A -1438 A/G polymorphism and CNV

The association between SNP rs6311 and OCD was first analyzed in only the 81 newly recruited patients with OCD (those not included in the previous study (Walitz et al. 2002)). There was a significant difference between the

Table 1 Demographic data

	<i>N</i>	Frequency (%)
<i>136 patients</i>		
Gender		
Male	77	56.6
Female	59	43.4
Age at investigation		13 ± 2.9 years (range 4.7–17.9 years)
Age at onset		11.1 ± 3.2 years (range 3–17.4 years)
Comorbid diagnosis		
None	74	54.4
ADHD	15	11.0
Anxiety disorders	10	7.4
Depression disorders	8	5.9
Eating disorders	5	3.7
Conduct disorders	4	2.9
Others*	7	5.1
Tic-disorder**	13	9.6
<i>106 controls</i>		
Gender		
Male	65	61.3
Female	41	38.7
Age		11.6 ± 2.6 years (range 5.1–17.8 years)

ADHD attention-deficit hyperactivity disorder

* Comorbidities as dyslexia, enuresis, histrionic personality disorder and behavioral and emotional disorders (as separation anxiety disorder of childhood, social anxiety disorder of childhood, depressive conduct disorder, elective mutism), which occur, respectively, only in one of the patients

** Lifetime-diagnosis of tic-disorder according to STOBS, without Tourette's syndrome

genotype distributions of controls and these OCD cases ($p = 0.030$). Note that the previous study, with a different control group and a smaller OCD group, also reported a significant association between genotype and OCD ($p = 0.046$). When all 135 available cases with SNP information were included, the association was highly significant ($p = 0.007$). We also found that patients with early onset OCD showed a higher frequency of the AA genotype (19.3%) compared to the healthy controls (16%) (Table 2). The estimated OR for the A allele was 1.69 [95% CI (1.17, 2.46); $p = 0.005$], adjusted for CNV. Assuming an additive effect of the A allele, this indicated that the risk of OCD was increased by 69% in patients with the heterozygous GA genotype and by 286% for the homozygous AA genotype.

The association (adjusted for SNP) between the HTR2A CNV ("low" vs. "normal/high") and OCD was also significant ($p = 0.020$). The SNP-adjusted OR estimated for a "low" CNV relative to a "normal/high" CNV was 7.56

Table 2 Frequencies of SNP rs6311 genotypes and CNV sizes in patients with early onset OCD and healthy controls

	Controls <i>N</i> (frequency %)	OCD <i>N</i> (frequency %)
Genotype (rs6311)		
GG	54 (50.9)	39 (28.9)
GA	35 (33.0)	70 (51.9)
AA	17 (16.0)	26 (19.3)
Fisher's exact test		$p = 0.002$
Armitage's test for trend		$p = 0.007$
Two-sided asymptotic (adjusted for CNV-pooled)		$p = 0.005$
CNV		
"Normal/high"	105 (99.1)	127 (94.1)
"Low"	1 (0.9)	8 (5.9)
Fisher's exact test		$p = 0.082$
Two-sided asymptotic (adjusted for SNP)		$p = 0.020$

One sample missing for the genotyping and one for CNV from technical reasons

[95% CI (1.32, 142.84)]. We did not find a significant gender effect in our case–control analysis ($p = 0.72$).

HTR2A –1438 A/G polymorphism and CNV associations with age of onset and severity of OCD

The HTR2A genotype was not significantly associated with age of onset or severity of OCD (Table 3a). In addition,

there was no significant difference between "normal" and "high" CNV with respect to age of onset or severity (t test $p = 0.47$ and $p = 0.30$, respectively). Because we hypothesized that the deletion ("low" CNV) would affect the phenotype by impairing the function of the promoter activity, we pooled the "normal" and "high" data into a joint "normal/high" CNV group for comparisons to the "low" CNV group (Table 3b). This analysis method revealed a significant association between "low" CNV and the age of onset ($p = 0.031$); the estimated average age of onset was 2.5 years earlier than that of the "normal/high" group [95% confidence interval (CI): (0.2 years, 4.8 years)]. Similarly, we observed a significant association between "low" CNV and the OCD severity measured with CY-BOCS scores ($p = 0.004$); the estimated average severity score was 8.7 points higher than that of the "normal/high" group [95% CI: (2.9 points, 14.5 points)].

Discussion

In this study, we confirmed the previously described association between the A allele of SNP rs6311 and early onset OCD (Walitza et al. 2002; Enoch et al. 2001). We estimated that the OR per A allele was 1.69 [95% CI (1.17, 2.46)] for early onset OCD, but we found no significant association between the A allele of SNP rs6311 and age of onset or OCD severity. This might be due to the fact that the OCD population in this study contained only patients

Table 3 Age at onset and severity of OCD, based on the SNP rs6311 genotype (A) and the CNV size (B)

A Genotype (rs6311)	Age at onset (years) (mean \pm SD)	<i>N</i>	Missing	CY-BOCS (score) (mean \pm SD)	<i>N</i>	Missing		
GG	11.0 \pm 3.3	38	1	23.9 \pm 8.4	34	5		
GA	10.9 \pm 3.3	65	5	21.7 \pm 7.0	66	4		
AA	11.7 \pm 2.6	25	1	21.0 \pm 8.4	26	0		
One-way ANOVA	$p = 0.55$			$p = 0.28$				
Two-way ANOVA (adjusted for CNV)	$p = 0.48$			$p = 0.29$				
Two-way ANOVA (adjusted for CNV-pooled)	$p = 0.44$			$p = 0.33$				
B CNV	Age at onset (years) (mean \pm SD)	Estimate (95% CI) (years)*	<i>N</i>	Missing	CY-BOCS (score) (mean \pm SD)	Estimate (95% CI) (score)*	<i>N</i>	Missing
"Normal/high"	11.2 \pm 3.0		120	7	21.7 \pm 7.6		119	8
"Low"	8.8 \pm 4.8	–2.5 (–0.2; –4.8)	8	0	30.6 \pm 3.7	8.7 (2.9; 14.5)	7	1
One-way ANOVA	$p = 0.036$				$p = 0.003$			
Two-way ANOVA*	$p = 0.031$				$p = 0.004$			

One sample missing for the genotyping from technical reasons

One sample missing for the CNV from technical reasons

* Estimates and confidence intervals (CIs) are adjusted for SNP

with very early onset of the disease (average age of onset was 11.1 ± 3.2 years, range 3–17.4 years). Thus, we could not rule out an age dependent association for the-rs6311 A allele. The association found in this study, without age dependence, could be consequence of polymorphism influencing HTR2A gene expression through the promoter activity. An extensive reporter gene assay suggested that the rs6311 SNP modulated HTR2A promoter activity (Parsons et al. 2004); however, another study on the effect of the rs6311 SNP on promoter activity revealed no significant difference in expression of HTR2A mRNA (Spurlock et al. 1998).

Several studies on the polymorphic imprinting have presented some conflicting results regarding monoallelic expression of HTR2A (Bunzel et al. 1998; Kato et al. 1996; Fukuda et al. 2006; Myers et al. 2007). Nevertheless, we investigated whether the rs6311 polymorphism on the promoter confirm association of previous findings in very early onset OCD, since current findings do show that specifically this particular SNP has transcriptional effects on the gene. A recent study reported an *in silico* selection of phenotypes that reflected different polymorphisms in the HTR2A gene (Piva et al. 2010). The SNP rs6311 was found to cause loss of the E2F1 transcription factor site and the gain of two other transcription factor sites (HAND1E47 and SMAD; see Fig. 1). Another investigation of epigenetic factors affected by rs6311 revealed that a newly created E47-binding site (A-allele), a glucocorticoid receptor-binding site at position -1420 , and an Sp1-binding site at CpG methylation site $+1224$ caused alterations in methylation rates at both -1420 and -1439 sites (Falkenberg et al. 2011). Therefore, modifiers should be taken into account in functional studies.

One problem with genetic analyses is the inability to completely match a control group or minimize ethnic differences between patients and controls. In the present study, we included 136 German children and adolescents with early onset OCD, of which 107 patients were children from Würzburg, Germany. All patients and controls were of German origin. Furthermore, all 106 healthy German children were also recruited at the Department of Child and Adolescent Psychiatry of the University of Würzburg; therefore, we assumed that we were able to minimize ethnic stratification.

We also found that one copy (deletion) of a CNV located near the rs6311 was associated with very early onset OCD and an increased CY-BOCS score, which was related to enhanced symptom severity. Of note, the frequency of this deletion in our OCD group ($n = 8$) was increased compared to that in the healthy controls ($n = 1$). Since this CNV is not yet reported in any platform such as DGV or any publication, little is known about its frequency or size. From our findings one could assume that according to its frequency in

control group that it is a rare CNV, but concerning the size further analysis should be conducted up/downstream the amplicon location. Characterizations of CNVs and their associated polymorphisms are important, because they may provide key links to understanding of the genetic basis of quantitative traits and the different susceptibilities to psychiatric diseases. An initial study that explored the effects of CNVs on gene expression in lymphoblastoid cell lines from human populations reported that changes in copy number explained nearly 20% of the detected gene expression variation (Stranger et al. 2007). This was suggested to result from altered dosages of genes that mapped within CNVs; however, it may also potentially result from the impact of CNVs on neighboring genes (Stranger et al. 2007). Recent studies have shown that CNVs can influence the expression of genes both within the CNV and outside the CNV, in the vicinity of up to half a megabase (Henrichsen et al. 2009). It was suggested that, for disorders like Williams–Beuren (WBS; MIM 194050), Prader–Willi (MIM 176270), Angelman (MIM 105830), and DiGeorge/velocardio-facial syndromes (DG/VCF; MIM 188400), patients with duplications might have different clinical syndromes and milder phenotypic features than those with deletions. This might be explained by the fact that excess information tends to be less detrimental to the organism than a deficiency (Zhang et al. 2009). This effect might explain our observations of the effect that the “low” CNV had on the HTR2A promoter region; this effect might also influence promoter activity. A potential mechanism might be the loss of transcription factor sites within the CNV deletion (Fig. 1). However, this theory requires further investigation.

Limitations of the present study: the small sample size is one of the main limitations of the study. Therefore, we believe that the relatively narrow phenotype (e.g. early onset OCD, without Tourette’s syndrome) as one of the strengths of the study. A limitation could be also that we have not used a special interview to exclude all autistic spectrum disorders. For future studies, we recommend to use interviews as the Kiddie-SADS in a recent version with a separate interview of autistic symptoms according to DSM-IV. As the HTR2A is imprinted, the results of the association studies (patients compared to controls) cannot be interpreted without caution. Nevertheless, these replicated findings of association of the 5HT2A promoter polymorphism with early onset OCD and with other psychiatric disorders lead us to the CNV analysis in the 5HT2A promoter region, which showed interesting and promising findings. Further independent and extended studies of the CNV as well as the SNP analysis in early onset OCD, but also in related disorders need to be performed. These findings may suggest additional applications for investigating the genomic effects associated with OCD in large-scale populations.

Acknowledgments We would like to express our gratitude to all participants. In addition, we would also like to thank M. Hofmann, T. Elpel, and G. Ortega for their excellent technical assistance. The study was supported by the Deutsche Forschungsgemeinschaft WA 1618 and the KFO 125.

Conflict of interest The authors declare no conflict of interest.

References

- American Psychiatric Association (1996) DSM-IV. Diagnostic and statistical manual of mental disorders. APA, Washington DC
- Beckmann JS, Estivill X, Antonarakis SE (2007) Copy number variants and genetic traits: closer to the resolution of phenotypic to genotypic variability. *Nat Rev Genet* 8:639–646
- Bray NJ, Buckland PR, Hall H, Owen MJ, O'Donovan MC (2004) The serotonin-2A receptor gene locus does not contain common polymorphism affecting mRNA levels in adult brain. *Mol Psychiatry* 9:109–114
- Bunzel R, Blumcke I, Cichon S, Normann S, Schramm J, Propping P, Nothen MM (1998) Polymorphic imprinting of the serotonin-2A (5-HT2A) receptor gene in human adult brain. *Brain Res Mol Brain Res* 59:90–92
- Cattell R, Weiß R, Osterland J (1997) Grundintelligenztest Skala 1-CFT1. Hogrefe Verlag, Göttingen
- De Luca V, Likhodi O, Kennedy JL, Wong AH (2007) Parent-of-origin effect and genomic imprinting of the HTR2A receptor gene T102C polymorphism in psychosis. *Psychiatry Res* 151:243–248
- Denys D, Van Nieuwerburgh F, Deforce D, Westenberg HG (2006) Association between serotonergic candidate genes and specific phenotypes of obsessive compulsive disorder. *J Affect Disord* 91:39–44
- Dickel DE, Veenstra-VanderWeele J, Bivens NC et al (2007) Association studies of serotonin system candidate genes in early-onset obsessive-compulsive disorder. *Biol Psychiatry* 61:322–329
- Dilling H, Freyberger HJ, Stieglitz RD (1996) ICD-10 field trial of the Diagnostic Criteria for Research in German-speaking countries. Introduction. *Psychopathology* 29:258–259
- Döpfner M, Plücker J, Bölte J, Lenz K, Melchers P, Heim K (1991) Arbeitsgruppe Deutsche child behavior checklist. Elternfragebogen über das Verhalten von Kindern und Jugendlichen; deutsche Bearbeitung der Child Behavior Checklist (CBCL/4-18). Einführung und Anleitung zur Handauswertung. In: Achenbach T (ed) Integrative Guide for the 1991 CBCL 4-18, YSR and TRF Profiles. University of Vermont, Department of Psychiatry, Köln, Arbeitsgruppe Kinder- Jugend- und Familiendiagnostik, Burlington, VT
- Döpfner M, Berner W, Flechtner H, Lehmkuhl G, Steinhausen H (1999) Psychopathologisches Befundsystem für Kinder und Jugendliche (CASCAP-D). Hogrefe Verlag, Göttingen
- Enoch MA, Kaye WH, Rotondo A, Greenberg BD, Murphy DL, Goldman D (1998) 5-HT2A promoter polymorphism –1438G/A, anorexia nervosa, and obsessive-compulsive disorder. *Lancet* 351:1785–1786
- Enoch MA, Greenberg BD, Murphy DL, Goldman D (2001) Sexually dimorphic relationship of a 5-HT2A promoter polymorphism with obsessive-compulsive disorder. *Biol Psychiatry* 49:385–388
- Falkenberg VR, Gurbaxani BM, Unger ER, Rajeevan MS (2011) Functional genomics of serotonin receptor 2A (HTR2A): interaction of polymorphism, methylation, expression and disease association. *Neuromolecular Med* 13:66–76
- Frisch A, Michaelovsky E, Rockah R et al (2000) Association between obsessive-compulsive disorder and polymorphisms of genes encoding components of the serotonergic and dopaminergic pathways. *Eur Neuropsychopharmacol* 10:205–209
- Fukuda Y, Koga M, Arai M et al (2006) Monoallelic and unequal allelic expression of the HTR2A gene in human brain and peripheral lymphocytes. *Biol Psychiatry* 60:1331–1335
- Geller DA, Biederman J, Stewart SE, Mullin B, Martin A, Spencer T, Faraone SV (2003) Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. *Am J Psychiatry* 160:1919–1928
- Grados MA, Samuels J, Shugart YY et al (2007) Rare plus common SERT variants in obsessive-compulsive disorder. *Mol Psychiatry* 12:422–423
- Hebebrand J, Klug B, Fimmers R et al (1997) Rates for tic disorders and obsessive compulsive symptomatology in families of children and adolescents with Gilles de la Tourette syndrome. *J Psychiatr Res* 31:519–530
- Hemmings SM, Kinnear CJ, Niehaus DJ, Moolman-Smook JC, Lochner C, Knowles JA, Corfield VA, Stein DJ (2003) Investigating the role of dopaminergic and serotonergic candidate genes in obsessive-compulsive disorder. *Eur Neuropsychopharmacol* 13:93–98
- Hemmings SM, Kinnear CJ, Lochner C, Seedat S, Corfield VA, Moolman-Smook JC, Stein DJ (2006) Genetic correlates in trichotillomania—a case-control association study in the South African Caucasian population. *Isr J Psychiatry Relat Sci* 43:93–101
- Henrichsen CN, Vinckenbosch N, Zollner S, Chagnat E, Pradervand S, Schutz F, Ruedi M, Kaessmann H, Reymond A (2009) Segmental copy number variation shapes tissue transcriptomes. *Nat Genet* 41:424–429
- Kato MV, Shimizu T, Nagayoshi M, Kaneko A, Sasaki MS, Ikawa Y (1996) Genomic imprinting of the human serotonin-receptor (HTR2) gene involved in development of retinoblastoma. *Am J Hum Genet* 59:1084–1090
- Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N (1997) Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. *J Am Acad Child Adolesc Psychiatry* 36:980–988
- Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 62:593–602
- Lee CH, Liu CM, Wen CC, Chang SM, Hwu HG (2010) Genetic copy number variants in sib pairs both affected with schizophrenia. *J Biomed Sci* 17:2
- Lesch KP, Selch S, Renner TJ et al (2011) Genome-wide copy number variation analysis in attention-deficit/hyperactivity disorder: association with neuropeptide Y gene dosage in an extended pedigree. *Mol Psychiatry* 16:491–503
- Martinez-Barrondo S, Saiz PA, Morales B, Garcia-Portilla MP, Coto E, Alvarez V, Bobes J (2005) Serotonin gene polymorphisms in patients with panic disorder. *Actas Esp Psiquiatr* 33:210–215
- Meira-Lima I, Shavitt RG, Miguita K, Ikenaga E, Miguel EC, Vallada H (2004) Association analysis of the catechol-o-methyltransferase (COMT), serotonin transporter (5-HTT) and serotonin 2A receptor (5HT2A) gene polymorphisms with obsessive-compulsive disorder. *Genes Brain Behav* 3:75–79
- Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. *Nucl Acids Res* 16:1215
- Myers RL, Airey DC, Manier DH, Shelton RC, Sanders-Bush E (2007) Polymorphisms in the regulatory region of the human

- serotonin 5-HT_{2A} receptor gene (HTR2A) influence gene expression. *Biol Psychiatry* 61:167–173
- Parsons MJ, D'Souza UM, Arranz MJ, Kerwin RW, Makoff AJ (2004) The –1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. *Biol Psychiatry* 56:406–410
- Pauls DL, Raymond CL, Stevenson JM, Leckman JF (1991) A family study of Gilles de la Tourette syndrome. *Am J Hum Genet* 48:154–163
- Pawitan Y (2001) *In all likelihood: statistical modelling and inference using likelihood*. Oxford University Press, USA
- Pediatric OCD Treatment Study (POTS) Team (2004) Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. *JAMA* 292:1969–1976
- Pinto D, Pagnamenta AT, Klei L et al (2010) Functional impact of global rare copy number variation in autism spectrum disorders. *Nature* 466:368–372
- Piva F, Giulietti M, Nardi B, Bellantuono C, Principato G (2010) An improved in silico selection of phenotype affecting polymorphisms in SLC6A4, HTR1A and HTR2A genes. *Hum Psychopharmacol* 25:153–161
- Polesskaya OO, Aston C, Sokolov BP (2006) Allele C-specific methylation of the 5-HT_{2A} receptor gene: evidence for correlation with its expression and expression of DNA methylase DNMT1. *J Neurosci Res* 83:362–373
- R Development Core Team (2010) *R: a language and environment for statistical computing*. R Foundation for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria
- Saiz PA, Garcia-Portilla MP, Arango C et al (2008a) Association study between obsessive-compulsive disorder and serotonergic candidate genes. *Prog Neuropsychopharmacol Biol Psychiatry* 32:765–770
- Saiz PA, Garcia-Portilla MP, Paredes B et al (2008b) Association between the A –1438G polymorphism of the serotonin 2A receptor gene and nonimpulsive suicide attempts. *Psychiatr Genet* 18:213–218
- Sasieni PD (1997) From genotypes to genes: doubling the sample size. *Biometrics* 53:1253–1261
- Scahill L, Riddle MA, McSwiggin-Hardin M, Ort SI, King RA, Goodman WK, Cicchetti D, Leckman JF (1997) Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. *J Am Acad Child Adolesc Psychiatry* 36:844–852
- Serretti A, Drago A, De Ronchi D (2007) HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. *Curr Med Chem* 14:2053–2069
- Slager SL, Schaid DJ (2001) Case-control studies of genetic markers: power and sample size approximations for Armitage's test for trend. *Hum Hered* 52:149–153
- Spurlock G, Heils A, Holmans P et al (1998) A family based association study of T102C polymorphism in 5HT_{2A} and schizophrenia plus identification of new polymorphisms in the promoter. *Mol Psychiatry* 3:42–49
- Stankiewicz P, Lupski JR (2010) Structural variation in the human genome and its role in disease. *Annu Rev Med* 61:437–455
- Stiensmeier-Pelster J, Schurmann M, Duda K (2000) *Depressions-Inventar für Kinder und Jugendliche (DIKJ)*, Hogrefe Verlag, Göttingen
- Stranger BE, Forrest MS, Dunning M et al (2007) Relative impact of nucleotide and copy number variation on gene expression phenotypes. *Science* 315:848–853
- Tot S, Erdal ME, Yazici K, Yazici AE, Metin O (2003) T102C and –1438 G/A polymorphisms of the 5-HT_{2A} receptor gene in Turkish patients with obsessive-compulsive disorder. *Eur Psychiatry* 18:249–254
- Unnewehr S, Schneider S, Margraf J (1995) *Kinder-DIPS: Diagnostisches Interview bei psychischen Störungen im Kindes- und Jugendalter*. Springer, Heidelberg
- van Grootheest DS, Cath DC, Beekman AT, Boomsma DI (2005) Twin studies on obsessive-compulsive disorder: a review. *Twin Res Hum Genet* 8:450–458
- Walitza S, Wewetzer C, Warnke A et al (2002) 5-HT_{2A} promoter polymorphism –1438G/A in children and adolescents with obsessive-compulsive disorders. *Mol Psychiatry* 7:1054–1057
- Walitza S, Wendland JR, Gruenblatt E, Warnke A, Sontag TA, Tucha O, Lange KW (2010) Genetics of early-onset obsessive-compulsive disorder. *Eur Child Adolesc Psychiatry* 19:227–235
- Williams NM, Zaharieva I, Martin A et al (2010) Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis. *Lancet* 376:1401–1408
- Zhang F, Gu W, Hurler ME, Lupski JR (2009) Copy number variation in human health, disease, and evolution. *Annu Rev Genomics Hum Genet* 10:451–481
- Zohar J, Chopra M, Sasson Y, Amiaz R, Amital D (2000) Obsessive compulsive disorder: serotonin and beyond. *World J Biol Psychiatry* 1:92–100